Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
holding | ELVN | Common Stock | 2.34M | Jun 2, 2022 | By entities affiliated with Arix Bioscience plc | F1 |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | ELVN | Stock Options (Right to Buy) | Award | $0 | +8.5K | $0.00 | 8.5K | Jun 2, 2022 | Common Stock | 8.5K | $1.07 | Direct | F2 |
Id | Content |
---|---|
F1 | The shares are directly beneficially owned by Arix Bioscience Holdings Limited ("Arix Ltd."). Arix Bioscience Plc ("Arix Plc") is the sole owner and parent of Arix Ltd. and may be deemed to indirectly beneficially own the shares held by Arix Ltd. Mr. Chin is a managing director of Arix plc. Each of Arix plc and Mr. Chin disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests therein. |
F2 | The option will vest on the first anniversary of the date of grant or, if earlier, the date of Imara's next annual meeting of stockholders following the date of grant. |